CVS Health (CVS) jumped 3.4% to $91.54 on November 3, 2026, the day before it reports earnings. Volume was heavy and none of the news we track explains the move. The weekly uptrend is intact, and the balance of evidence for the next two to six weeks leans positive with medium conviction: the stock leads the S&P 500 but trails the healthcare sector. A daily close above $92.68 on above-average volume would be the first sign that buyers are back.
Why it matters
There is no CVS-specific event behind today's rise. The news around the stock is about the industry. Dexcom's quarter shows healthcare earnings are being received well: Seeking Alpha reports it raised full-year revenue guidance to $5.20–$5.25 billion and authorized another $1 billion buyback. The pressure point is Medicare Advantage. Yahoo Finance says Humana, UnitedHealth and Aetna, which is part of CVS, are cutting coverage or leaving markets for 2027, affecting about 3.2 million enrollees. The causes it gives are lower government reimbursement and rising medical costs.
Much of the good news is already in the price. CVS is up 14.4% year to date and 5.0% over the past month. It peaked at $94.75 on October 20, 2026 and sat 3.4% below that level at today's price. Today's 3.4% gain came on volume 69% above its 20-day average, while the sector ETF XLV slipped 0.2% and the S&P 500 rose 0.2%. That points to stock-specific buying ahead of the print, but nothing in the news confirms the cause, so treat it as positioning rather than information.
Over five days the market did most of the damage and the sector did most of the lifting. The S&P 500 fell 2.1% and XLV rose 2.8%, while CVS slipped 0.4%. That is better than the market but 3.2 points behind the sector. The 50-day picture is similar: CVS leads the S&P 500 by 2.2 points and trails XLV by 5.9. Healthcare has gained 10.9% in a month and CVS only 5.0%, so the sector rally has largely passed CVS by.
The argument about CVS has two sides. Bulls point to a turnaround that is working. The Motley Fool notes revenue rose more than 7% to $106.1 billion and the 2026 diluted EPS forecast was lifted to $6.84–$7.04 from $6.24–$6.44. Seeking Alpha adds a dividend yield near 3%. On the chart, CNBC cites an analyst who sees the $82 to $86 range as key support. Skeptics focus on the economics of insurance. Yahoo Finance carries Mark Cuban's claim that companies using AI to audit their health plans found overcharging by insurers including CVS, UnitedHealth and Cigna. In a second piece he urges investors to drop insurer holdings from their 401(k)s. A Department of Labor rule requiring pharmacy benefit managers to disclose rebates and spread pricing, covered by Benzinga and effective in July, adds to the transparency pressure on the industry.
Analysts sit firmly on the bulls' side. Twenty-five of them rate CVS a strong buy, with a mean price target of $115.52. The stock is 20.8% below that, and even the lowest target, $103, is above today's price. The highest is $146. That spread says the Street expects the turnaround to continue. It also means the stock needs earnings to confirm that view, not just to avoid disappointing.
What the evidence says
The long-term thesis is intact. The price is above its 40-week average, above the 50-day average at $91.08 and above the 200-day at $88.89. Over 200 days CVS has performed in line with the S&P 500, a 0.1-point lag. It is 17.2% below its 52-week high of $110.60 and 30.6% above its low of $70.08. That is a stock in recovery, trading in the lower half of that range, not one in a fresh uptrend at its highs. RSI at 53 shows neither stretched nor oversold conditions.
For the next two to six weeks the balance of evidence leans positive, with medium conviction: two of four points. The daily trend runs with the weekly uptrend, which is the strongest support. CVS also leads the S&P 500 over 50 days. The other half of the picture holds conviction back. The stock lags its own sector over the same period and has done so over the past five days, which is the wrong direction for a stock that should be gaining sector support.
The strongest case against this reading is that CVS is 0.46 above its 50-day average and still under the $92.68 level that has capped it. The Medicare Advantage cutbacks and the Cuban criticism show the cost and pricing pressures that could surface in tomorrow's report. A stock that has run 3.4% on thin explanation into a binary event can give that back quickly. That does not tip the balance, because the trend structure is still intact and the support levels are close. It is a reason the conviction is medium and not high.
Levels that matter
The structure holds above $91.08, the 50-day average. A close below it would be the first crack, and the price is only a few tenths above it. Below that, $90 is a round-number floor. The trend itself ends below $88.89, the 200-day average, on a weekly close. Further down, $84.12 and $81.46 are the next swing zones, which overlap with the area CNBC's analyst flagged.
The breakout level is a daily close above $92.68 on volume above its 20-day average. From there the first target is $98.15, giving 2.6 to 1, and the second is the 52-week high at $110.60, giving 8.4 to 1. The stop is $90.54, which is the 50-day average minus a quarter of the 14-day ATR; a breakout that falls back below that level would have failed. The math reaches 3 to 1 only by way of the second target, and the $100 round number lies in between as a likely pause.
What would change the picture
A weekly close below $88.89, the 200-day average, would change the picture, because it would end the weekly uptrend that the positive reading rests on. The non-price fact most likely to cause it is a cut to the 2026 EPS guidance of $6.84–$7.04, or a medical-cost warning in the earnings report, which would validate the skeptics' case.
What to watch
- Earnings on November 4, 2026: the number that matters is the full-year EPS guidance against the $6.84–$7.04 range. Medical-cost trends in the insurance business are the main swing factor.
- Sector events: insurers' Medicare Advantage exits for 2027, the pharmacy benefit manager disclosure rule due in July, and this week's healthcare earnings, including Cardinal Health, per CNBC. The midterm elections and the October jobs report land the same week.
- Valuation: at $91.54 CVS trades 20.8% below the $115.52 mean target and below the lowest target of $103. The gap is the case for upside, and it will only close if the earnings numbers support it.